Cargando…

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation

Even though allogeneic stem cell transplantation is the most intensive treatment for acute myeloid leukemia (AML), chemo-resistant leukemia relapse is still one of the most common causes of death for these patients, as is transplant-related mortality, i.e., graft versus host disease, infections, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruserud, Øystein, Tsykunova, Galina, Hernandez-Valladares, Maria, Reikvam, Hakon, Tvedt, Tor Henrik Anderson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147490/ https://www.ncbi.nlm.nih.gov/pubmed/34063204 http://dx.doi.org/10.3390/ph14050423

Ejemplares similares

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
por: Fredly, Hanne, et al.
Publicado: (2013)

Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid
por: Ersvaer, Elisabeth, et al.
Publicado: (2015)

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid
por: Hernandez-Valladares, Maria, et al.
Publicado: (2021)

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
por: Lindås, Roald, et al.
Publicado: (2014)

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2021)

IL-6 Responsiveness of CD4(+) and CD8(+) T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2022)

Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation
por: Tvedt, Tor Henrik, et al.
Publicado: (2016)

Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2019)

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
por: Nepstad, Ina, et al.
Publicado: (2018)

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients
por: Hatfield, Kimberley Joanne, et al.
Publicado: (2022)

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation
por: Reikvam, Håkon, et al.
Publicado: (2015)

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors—Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2018)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2013)

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target
por: Tvedt, Tor Henrik Anderson, et al.
Publicado: (2017)

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020)

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013)

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2021)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients
por: Johansen, Silje, et al.
Publicado: (2018)

Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome
por: Reikvam, Håkon, et al.
Publicado: (2015)

All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism
por: Benjamin, Dalyia N., et al.
Publicado: (2022)

Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis
por: Bruserud, Øyvind, et al.
Publicado: (2021)

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients
por: Bruserud, Øystein, et al.
Publicado: (2023)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2022)

Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers
por: Reikvam, Håkon, et al.
Publicado: (2018)

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity
por: Bartaula-Brevik, Sushma, et al.
Publicado: (2023)

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells
por: Brenner, Annette K., et al.
Publicado: (2016)

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience?
por: Bruserud, Øystein, et al.
Publicado: (2020)

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies
por: Ersvaer, Elisabeth, et al.
Publicado: (2011)

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms
por: Brenner, Annette K., et al.
Publicado: (2014)

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis
por: Mosevoll, Knut Anders, et al.
Publicado: (2014)

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
por: Raffoux, Emmanuel, et al.
Publicado: (2010)

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
por: Leitch, Calum, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_en5lb515pvq1sbbgsvrn70ut5s